Logo Image

Shorts

AAN 2026: Function and Use of Newly Approved Cala kIQ Plus Device
0:45
AAN 2026: Function and Use of Newly Approved Cala kIQ Plus Device
2 months ago
by
Kate Hornbluth, PhD
AAN 2026: Clinical Pearls for Identifying and Treating CNS Vasculitis
0:45
AAN 2026: Clinical Pearls for Identifying and Treating CNS Vasculitis
2 months ago
by
Edith Graham, MD
What Advice Would you Give to Neurologists Starting Their Careers?
0:31
What Advice Would you Give to Neurologists Starting Their Careers?
2 months ago
by
Jorge G. Ortiz Garcia , MD, MSCR, FAAN(+1 more)
AAN 2026: Call to Action on Epilepsy for the Wider Neurology Community
0:19
AAN 2026: Call to Action on Epilepsy for the Wider Neurology Community
2 months ago
by
Anup Patel, MD
AAN 2026: Key Facts About Huntington Disease Neurologists Should Know
1:05
AAN 2026: Key Facts About Huntington Disease Neurologists Should Know
2 months ago
by
Victor Sung, MD
What is the Biggest Piece of Misinformation in Neurology Right Now?
0:31
What is the Biggest Piece of Misinformation in Neurology Right Now?
2 months ago
by
Jonathan E. Howard, MD(+1 more)
AAN 2026: Notable Advances and Overused Buzzwords
1:05
AAN 2026: Notable Advances and Overused Buzzwords
2 months ago
by
Johan Luthman, PhD
2026 AAN Annual Meeting: Trends to Watch
1:05
2026 AAN Annual Meeting: Trends to Watch
2 months ago
by
Paul George, MD, PhD, FAAN(+1 more)
Key Focus Areas of the 2026 AAN Meeting
1:12
Key Focus Areas of the 2026 AAN Meeting
2 months ago
by
Paul George, MD, PhD, FAAN(+1 more)
Emerging Concepts on the Horizon for Neurointerventional Surgery
1:28
Emerging Concepts on the Horizon for Neurointerventional Surgery
2 months ago
by
Marco Meglio(+1 more)
Functionality of Zeto One EEG Headset for Seizure Detection
1:28
Functionality of Zeto One EEG Headset for Seizure Detection
2 months ago
by
Marco Meglio(+1 more)
Clinical Considerations to Optimize Neurointerventional Surgery
1:28
Clinical Considerations to Optimize Neurointerventional Surgery
2 months ago
by
Marco Meglio(+1 more)
Emerging Targeted Therapies for Myasthenia Gravis
1:26
Emerging Targeted Therapies for Myasthenia Gravis
2 months ago
by
Isabella Ciccone, MPH(+1 more)
Design Considerations for Stem-Cell Based MS Trials
1:33
Design Considerations for Stem-Cell Based MS Trials
2 months ago
by
Jeffrey Cohen, MD(+1 more)
Phase 3 Updates for MASCOT Trial of MSA Agent Amlenetug
1:06
Phase 3 Updates for MASCOT Trial of MSA Agent Amlenetug
2 months ago
by
Marco Meglio(+1 more)
Why Pediatric Stroke Collaboration Matters
0:44
Why Pediatric Stroke Collaboration Matters
2 months ago
by
Beth Cavanaugh, MD(+1 more)
Understanding Mechanism of Investigational Lu AF28996 in Parkinson Disease
1:06
Understanding Mechanism of Investigational Lu AF28996 in Parkinson Disease
2 months ago
by
Marco Meglio(+1 more)
Recapping the 2026 ACTRIMS Forum
1:18
Recapping the 2026 ACTRIMS Forum
2 months ago
by
Isabella Ciccone, MPH(+1 more)
FDA Approval of High-Dose Nusinersen for Spinal Muscular Atrophy
1:06
FDA Approval of High-Dose Nusinersen for Spinal Muscular Atrophy
2 months ago
by
Marco Meglio(+1 more)
Living a Full Life with MS: Finding Hope and Specialized Care
1:25
Living a Full Life with MS: Finding Hope and Specialized Care
2 months ago
by
Constance V. Katsafanas, DO(+1 more)
Treating RLS Without Drug Interactions
1:07
Treating RLS Without Drug Interactions
2 months ago
by
Louie Pasculli(+1 more)
MS Roundtable: Educational Changes Needed With New Diagnostic Criteria
0:45
MS Roundtable: Educational Changes Needed With New Diagnostic Criteria
2 months ago
by
Marco Meglio(+1 more)
MS Roundtable: Treating Multiple Sclerosis Before Symptoms Arise
1:17
MS Roundtable: Treating Multiple Sclerosis Before Symptoms Arise
2 months ago
by
Marco Meglio(+1 more)
MS Roundtable: Top Takeaways From 2024 McDonald Criteria
1:17
MS Roundtable: Top Takeaways From 2024 McDonald Criteria
2 months ago
by
Marco Meglio(+1 more)
Purple Day: Exciting, Novel Treatments on the Horizon for Epilepsy
1:17
Purple Day: Exciting, Novel Treatments on the Horizon for Epilepsy
2 months ago
by
Marco Meglio(+1 more)
Overviewing Phase 3 DAWN Efficacy Data of Daratumumab in NMOSD
0:35
Overviewing Phase 3 DAWN Efficacy Data of Daratumumab in NMOSD
2 months ago
by
Michael Levy, MD, PhD(+1 more)
Why Some RLS Medications Can Make Symptoms Worse
0:58
Why Some RLS Medications Can Make Symptoms Worse
2 months ago
by
Louie Pasculli
Meeting the Needs of Underserved Multiple Sclerosis Populations
1:33
Meeting the Needs of Underserved Multiple Sclerosis Populations
3 months ago
by
Marisa McGinley, DO(+1 more)
Early Identification and Newborn Screening for Neuromuscular Disorders
0:37
Early Identification and Newborn Screening for Neuromuscular Disorders
3 months ago
by
John F. Brandsema, MD(+1 more)
Data Behind EBNA1 Antibodies as Distinguishable Feature of Multiple Sclerosis
2:00
Data Behind EBNA1 Antibodies as Distinguishable Feature of Multiple Sclerosis
3 months ago
by
Marco Meglio